



**Contact:**

David Waldman or Justyna Gudaszewska  
Crescendo Communications, LLC  
Email: [mmd@crescendo-ir.com](mailto:mmd@crescendo-ir.com)  
Tel: +48 693 354 580

**Milestone Medical's CompuFlo® Epidural Instrument Featured in Abstract Presented at the 36th Annual Congress of The European Society of Regional Anaesthesia & Pain Therapy**

**LIVINGSTON, NJ, September 20, 2017 -- Milestone Medical Inc. (WAR:MMD)** today announced that an abstract featuring the CompuFlo® epidural instrument was presented on September 13, 2017 at the 36th Annual European Society of Regional Anaesthesia & Pain Therapy (ESRA) Congress 2017, in Lugano, Switzerland. The European Society of Regional Anesthesia & Pain Therapy has a current membership of over 3,500 of the leading anesthesiologists in Europe.

The Abstract, entitled, "Safe Localization of the Epidural Space with the CompuFlo® After Accidental Dural Puncture During Labor Neuraxial Analgesia, A Case Report", was presented at the ESRA Academy by Dr. Vittorio Limatola, a medical doctor from the University of Naples - Italy (2003), with a specialization in anesthesia at the University of Pisa - Italy (2008). Dr. Limatola was an Honorary Research Fellow at the Imperial College of London - UK (2006) and has worked at the Obstetric Unit at A.O.U. Careggi of Florence, Italy, since 2009.

Daniel Goldberger, Chief Executive Officer of Milestone Medical, stated, "We are pleased to have our technology featured by a leading anesthesiologist at one of the premier industry conferences in Europe. This case report demonstrates the value and effectiveness of CompuFlo® in identifying and locating the epidural space, especially in complicated cases, such as the one in this case report. In this particular case, the standard loss of resistance technique not only failed to locate the epidural space, but also led to a complication, known as accidental dural puncture, which caused the patient a severe headache that required a subsequent intervention. As a result, an epidural blood patch was successfully performed using the CompuFlo® instrument to repair the dural defect. This is clear illustration of the mounting clinical experience with CompuFlo, as it continues to meet new challenges in difficult patients, demonstrating its value as an everyday epidural confirmation solution for all patients."

***About Milestone Medical Inc.***

Milestone Medical, Inc. has developed epidural and intra-articular drug delivery systems based on a patented, painless, computer-controlled injection and drug delivery technology originally developed by Milestone Scientific, Inc. Development of both the epidural and intra-articular instruments is now complete. The Company was granted the FDA marketing clearance of the epidural instrument in U.S. and is currently pursuing regulatory approval for intra-articular instrument in the U.S. Milestone Medical received CE Mark approval to sell and market its intra-articular and epidural instruments across European Union. For more information please visit [www.medicalmilestone.com](http://www.medicalmilestone.com).

***About Milestone Scientific Inc.***

Milestone Scientific Inc. (MLSS) is a leading medical research and development company that designs and patents innovative injection technologies. Milestone's computer-controlled systems are designed to make injections precise, efficient, and virtually painless. For more information please visit our website: [www.milestonescientific.com](http://www.milestonescientific.com).

***Safe Harbor Statement***

*This press release contains forward-looking statements regarding the timing and financial impact of Milestone's ability to implement its business plan, expected revenues, timing of regulatory approvals and future success.*

*These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions, future business decisions and regulatory developments, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone's control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone's periodic filings with the Securities and Exchange Commission, including without limitation, Milestone's Annual Report for the year ended December 31, 2016. The forward looking statements in this press release are based upon management's reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason.*